Tag archive for ‘Galderma’
NovaBay: Data from Phase II Trial of Auriclosene in Urinary Catheter Blockage and Encrustation is Imminent (NBY, $1.40)
Company Overview and Purpose of the Report NovaBay (NBY) will be reporting the results of three Phase II clinical trials involving its first in class “non-antibiotic”, anti-microbial agent auriclosene (NVC-422) over the next three quarters. The mechanism of action and previously conducted phase I and II trials indicate that it has broad spectrum activity against […]